Literature DB >> 21763678

Overexpression of the β subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis.

Xiaoqing Guo1, Guangzhi Liu, Isaiah G Schauer, Gong Yang, Imelda Mercado-Uribe, Fan Yang, Shiwu Zhang, Yuanli He, Jinsong Liu.   

Abstract

Ovarian carcinoma is the most lethal gynecologic malignancy, however underlying molecular events remain elusive. Expression of human chorionic gonadotropin β subunit (β-hCG) is clinically significant for both trophoblastic and nontrophoblastic cancers; however, whether β-hCG facilitates ovarian epithelial cell tumorigenic potential remains uncharacterized. Immortalized nontumorigenic ovarian epithelial T29 and T80 cells stably overexpressing β-hCG were examined for alterations in cell cycle and apoptotic status by flow cytometry, expression of proteins regulating cell cycle and apoptosis by Western blot, proliferation status by MTT assay, anchorage-independent colony formation, and mouse tumor formation. Immunoreactivity for β-hCG was evaluated using mouse xenografts and on human normal ovarian, fallopian tube, endometrium, and ovarian carcinoma tissues. T29 and T80 cells overexpressing β-hCG demonstrated significantly increased proliferation, anchorage-independent colony formation, prosurvival Bcl-X(L) protein expression, G2-checkpoint progression, elevated cyclins E/D1 and Cdk 2/4/6, and decreased apoptosis. Collectively, these transformational alterations in phenotype facilitated increased xenograft tumorigenesis (P < 0.05). Furthermore, β-hCG immunoreactivity was elevated in malignant ovarian tumors, compared with normal epithelial expression in ovaries, fallopian tube, and endometrium (P < 0.001). Our data indicate that elevated β-hCG transforms ovarian surface epithelial cells, facilitating proliferation, cell cycle progression, and attenuated apoptosis to promote tumorigenesis. Our results further decipher the functional role and molecular mechanism of β-hCG in ovarian carcinoma. β-hCG may contribute to ovarian cancer etiology, which introduces a new therapeutic intervention target for ovarian cancer.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21763678      PMCID: PMC3157261          DOI: 10.1016/j.ajpath.2011.05.018

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 2.  Choriocarcinoma. A model for tumour markers.

Authors:  K D Bagshawe
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

Review 3.  Glycoprotein hormones: structure and function.

Authors:  J G Pierce; T F Parsons
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

4.  Human chorionic gonadotropin, its free subunits and gestational trophoblastic disease.

Authors:  M Ozturk
Journal:  J Reprod Med       Date:  1991-01       Impact factor: 0.142

5.  Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin.

Authors:  Susana B Rulli; Aino Kuorelahti; Oznur Karaer; Lauri J Pelliniemi; Matti Poutanen; Ilpo Huhtaniemi
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

6.  Localization of human chorionic gonadotropin beta subunit transcripts in ovarian cancer tissue.

Authors:  Ewa Nowak-Markwitz; Anna Jankowska; Anna Szczerba; Miroslaw Andrusiewicz; Jerzy B Warchoł
Journal:  Folia Histochem Cytobiol       Date:  2004       Impact factor: 1.698

7.  Expression of beta-human chorionic gonadotropin in ovarian cancer tissue.

Authors:  E Nowak-Markwitz; A Jankowska; M Andrusiewicz; A Szczerba
Journal:  Eur J Gynaecol Oncol       Date:  2004       Impact factor: 0.196

8.  A genetically defined model for human ovarian cancer.

Authors:  Jinsong Liu; Gong Yang; Jennifer A Thompson-Lanza; Armand Glassman; Kimberly Hayes; Andrea Patterson; Rebecca T Marquez; Nelly Auersperg; Yinhua Yu; William C Hahn; Gordon B Mills; Robert C Bast
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

9.  Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression.

Authors:  Gong Yang; Kathy Qi Cai; Jennifer A Thompson-Lanza; Robert C Bast; Jinsong Liu
Journal:  J Biol Chem       Date:  2003-11-18       Impact factor: 5.157

10.  Serum and urinary levels of beta human chorionic gonadotrophin in patients with transitional cell carcinoma.

Authors:  J McLoughlin; T Pepera; J Bridger; G Williams
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

View more
  17 in total

Review 1.  The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis.

Authors:  Katie Lin; Stavroula Baritaki; Silvia Vivarelli; Luca Falzone; Aurora Scalisi; Massimo Libra; Benjamin Bonavida
Journal:  Antioxidants (Basel)       Date:  2022-06-17

2.  CGB activates ERK and AKT kinases in cancer cells via LHCGR-independent mechanism.

Authors:  Aleksandra Głodek; Anna Jankowska
Journal:  Tumour Biol       Date:  2014-02-20

3.  Vaccination with the repeat β-hCG C-terminal peptide carried by heat shock protein-65 (HSP65) for inducing antitumor effects.

Authors:  Jie Yang; Yankai Zhang; Huaqian Wang; Zhenqiu Gao; Zeyu Wang; Bin Liu; Xiuhua Zhang; Mingzhu Du; Xiao Huang; Maolei Xu; Jie Wu; Taiming Li; Jingjing Liu; Rongyue Cao
Journal:  Tumour Biol       Date:  2012-07-29

4.  TGF-β-induced hCG-β regulates redox homeostasis in glioma cells.

Authors:  Fahim Ahmad; Sadashib Ghosh; Sanchari Sinha; Shanker Datt Joshi; Veer Singh Mehta; Ellora Sen
Journal:  Mol Cell Biochem       Date:  2014-10-10       Impact factor: 3.396

5.  Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.

Authors:  Miriam Lenhard; Alexandra Tsvilina; Lan Schumacher; Markus Kupka; Nina Ditsch; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-01-03       Impact factor: 4.430

6.  Human chorionic gonadotropin β regulates epithelial-mesenchymal transition and metastasis in human ovarian cancer.

Authors:  Na Liu; Shu-Min Peng; Guang-Xi Zhan; Jing Yu; Wei-Min Wu; Hao Gao; Xiao-Feng Li; Xiao-Qing Guo
Journal:  Oncol Rep       Date:  2017-07-14       Impact factor: 3.906

7.  hCG production by mucinous adenocarcinoma of the ovary in a reproductive aged woman.

Authors:  Vincent Wagner; Heather Winn; Andreea Newtson; David Bender; Megan McDonald
Journal:  Gynecol Oncol Rep       Date:  2018-10-31

8.  Screening of feature genes of the ovarian cancer epithelia with DNA microarray.

Authors:  Huanchun Ying; Jing Lv; Tianshu Ying; Jun Li; Qing Yang
Journal:  J Ovarian Res       Date:  2013-06-05       Impact factor: 4.234

9.  Gonadotropins activate oncogenic pathways to enhance proliferation in normal mouse ovarian surface epithelium.

Authors:  Tyvette S Hilliard; Dimple A Modi; Joanna E Burdette
Journal:  Int J Mol Sci       Date:  2013-02-28       Impact factor: 5.923

10.  BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.

Authors:  S K Sengodan; R Nadhan; R S Nair; S K Hemalatha; V Somasundaram; R R Sushama; A Rajan; N R Latha; G R Varghese; R K Thankappan; J M Kumar; A Chil; T V Anilkumar; P Srinivas
Journal:  Oncogenesis       Date:  2017-09-04       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.